GO:0043117 positive regulation of vascular permeability: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0043117 (positive regulation of vascular permeability) describes any process that increases the extent to which blood vessels can be pervaded by fluid, a hallmark of inflammation, angiogenesis, and tumor progression.
• VEGF-A is the best-characterized inducer of vascular permeability, acting through VEGFR2 to disrupt endothelial adherens junctions and increase fluid extravasation.
• Neuropilin-1, PLCβ2, S100A8/A9, and Robo4 are key molecular regulators that either promote or suppress vascular permeability in a context-dependent manner.
• Dysregulated vascular permeability contributes to sepsis, COVID-19, cancer, retinal edema, and lymphedema, making it a therapeutic target.
• Tumor vessel normalization via anti-VEGF therapy reduces permeability and improves immune cell infiltration, linking permeability control to immunotherapy.
• CRISPR-based knockout, knock-in, and overexpression models enable causal dissection of genes controlling vascular permeability in endothelial cells and animal models.
Description
Positive regulation of vascular permeability (GO:0043117) is a biological process that increases the extent to which blood vessels can be pervaded by fluid, a fundamental feature of vascular biology with broad implications for health and disease. This process is essential for normal physiological functions such as immune cell extravasation and tissue repair, but when dysregulated it drives pathological edema, inflammation, and tumor progression. Understanding the molecular players that positively regulate vascular permeability is critical for developing targeted therapies against conditions ranging from sepsis to retinal vascular diseases. The term encompasses signaling events triggered by factors like vascular endothelial growth factor (VEGF), which disrupt endothelial cell-cell junctions and increase transendothelial fluid flux. Recent studies have identified additional regulators, including Neuropilin-1, PLCβ2, and S100A8/A9, that modulate permeability through distinct mechanisms. This article synthesizes authoritative QuickGO data and verified PubMed literature to provide a research-grade overview of GO:0043117, covering its definition, mechanisms, key genes, disease relevance, and experimental models for investigation.
positive regulation of vascular permeability At A Glance
| GO ID | GO:0043117 |
|---|---|
| GO term | positive regulation of vascular permeability |
| Ontology | biological_process |
| Synonym | activation of vascular permeability; stimulation of vascular permeability; up regulation of vascular permeability; up-regulation of vascular permeability; upregulation of vascular permeability |
| Major function | Increases the extent to which blood vessels can be pervaded by fluid, facilitating fluid and solute exchange, immune cell extravasation, and tissue remodeling. |
| Related process | Vascular permeability, angiogenesis, inflammation, endothelial barrier function |
| Key inducers | VEGF-A, histamine, thrombin, bradykinin, S100A8/A9 |
| Key suppressors | Robo4, angiopoietin-1, sphingosine-1-phosphate |
| Disease relevance | Sepsis, COVID-19, cancer, retinal edema, lymphedema, inflammation |
What Is GO:0043117?
GO:0043117, positive regulation of vascular permeability, is defined as any process that increases the extent to which blood vessels can be pervaded by fluid. In practical terms, it refers to the molecular and cellular events that enhance the leakiness of blood vessel walls, allowing fluid, solutes, and cells to move from the bloodstream into surrounding tissues. This process is distinct from negative regulation (which reduces permeability) and is often triggered by inflammatory mediators, growth factors, and cytokines that act on endothelial cells lining the vasculature.
Why Is positive regulation of vascular permeability Important in Cell Biology?
Positive regulation of vascular permeability is critically important because it underlies both normal physiology and numerous pathologies. In healthy tissues, controlled increases in permeability enable immune surveillance, nutrient delivery, and wound healing. However, excessive or sustained permeability leads to edema, tissue damage, and organ dysfunction, as seen in sepsis, acute respiratory distress syndrome, and diabetic retinopathy. In cancer, tumor-secreted VEGF increases vascular permeability, promoting metastasis and immunosuppression; anti-VEGF therapies that normalize tumor vessels can improve drug delivery and immune cell infiltration. Furthermore, vascular permeability is a central mechanism in emerging infectious diseases such as COVID-19, where endothelial barrier disruption contributes to severe outcomes. Thus, understanding GO:0043117 is essential for developing therapies that modulate vascular leak in diverse clinical settings.
• VEGF-A is the prototypical positive regulator of vascular permeability and a validated drug target in oncology and ophthalmology.
• Neuropilin-1 controls vascular permeability through juxtacrine regulation of endothelial adherens junctions, highlighting cell-cell contact mechanisms.
• PLCβ2 promotes VEGF-induced vascular permeability, linking phospholipase signaling to endothelial barrier disruption.
• S100A8/A9 deficiency attenuates pulmonary microvascular leakage in septic mice, implicating alarmins in permeability regulation.
• Robo4 upregulation by SMAD signaling suppresses vascular permeability and mortality in endotoxemia and COVID-19 models.
• Tumor vessel normalization via anti-VEGF therapy reduces permeability and enhances immunostimulatory reprogramming.
• Sustained VEGF suppression is a therapeutic strategy for retinal and choroidal vascular diseases characterized by increased permeability.
• Lymphedema involves impaired lymphatic drainage and altered vascular permeability, with emerging molecular targets.
• Permeability assays are essential for drug development, especially for anti-inflammatory and anti-angiogenic agents.
• CRISPR screens can identify novel regulators of vascular permeability, accelerating target discovery.
What Happens During positive regulation of vascular permeability?
Initiation by Permeability-Inducing Factors
In simple terms: Certain molecules in the blood or tissues signal blood vessels to become leaky.
The process begins when permeability-inducing factors such as VEGF-A, histamine, thrombin, or S100A8/A9 bind to receptors on endothelial cells. VEGF-A, historically known as vascular permeability factor, is the most potent and well-studied inducer. These factors activate intracellular signaling cascades that ultimately disrupt the endothelial barrier. For example, S100A8/A9 promotes pulmonary microvascular leakage in sepsis, and its deficiency attenuates this effect.
Endothelial Cell Signaling and Junction Disruption
In simple terms: Signals inside the cells cause the connections between cells to loosen.
Upon receptor activation, endothelial cells initiate signaling events that lead to the phosphorylation of adherens junction proteins such as VE-cadherin, causing them to internalize and weakening cell-cell adhesion. Neuropilin-1 has been shown to control vascular permeability through juxtacrine regulation of endothelial adherens junctions. PLCβ2 also promotes VEGF-induced vascular permeability, likely by generating second messengers that increase intracellular calcium and activate contractile machinery. These events result in the formation of gaps between endothelial cells, allowing fluid and solutes to escape.
Cytoskeletal Rearrangement and Gap Formation
In simple terms: The cell skeleton contracts, pulling cells apart to create openings.
Activation of RhoA/Rho kinase and myosin light chain kinase leads to actomyosin contraction, which pulls endothelial cells apart and stabilizes gaps. This cytoskeletal rearrangement is a key step in increasing permeability. The process is tightly regulated by phosphorylation events and second messengers such as calcium and diacylglycerol downstream of PLCβ2.
Resolution and Negative Feedback
In simple terms: The leakiness is eventually turned off to restore normal barrier function.
To prevent excessive edema, endogenous negative regulators such as Robo4 and angiopoietin-1 counteract permeability-inducing signals. Robo4 upregulation by SMAD signaling suppresses vascular permeability and mortality in endotoxemia and COVID-19 models. Additionally, sphingosine-1-phosphate signaling promotes barrier integrity. The balance between positive and negative regulation determines net vascular permeability.
Key Genes Involved in GO:0043117 positive regulation of vascular permeability
The following genes and proteins are central to the positive regulation of vascular permeability, as supported by verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| VEGFA | Primary inducer of vascular permeability; binds VEGFR2 to disrupt junctions | Target of anti-angiogenic therapies; biomarker in retinal and tumor diseases |
| NRP1 | Co-receptor for VEGF; regulates adherens junctions via juxtacrine signaling | Modulates permeability in angiogenesis and inflammation |
| PLCB2 | Phospholipase generating IP3 and DAG; promotes VEGF-induced permeability | Potential target for reducing edema |
| S100A8 | Alarmin that promotes microvascular leakage in sepsis | Biomarker and therapeutic target in inflammatory diseases |
| S100A9 | Forms heterodimer with S100A8; amplifies permeability | Involved in septic lung injury |
| ROBO4 | Endothelial receptor that suppresses permeability when upregulated by SMAD signaling | Protective in endotoxemia and COVID-19 |
| KDR (VEGFR2) | Receptor tyrosine kinase mediating VEGF-induced permeability | Drug target in oncology and ophthalmology |
| CDH5 (VE-cadherin) | Adherens junction protein; phosphorylation leads to barrier disruption | Key effector of permeability |
| RHOA | Small GTPase mediating cytoskeletal contraction and gap formation | Downstream of PLCβ2 in permeability |
| ROCK1 | Rho kinase; promotes actomyosin contraction | Involved in endothelial barrier disruption |
| SMAD1/5/8 | Transcription factors that upregulate Robo4 and suppress permeability | Protective signaling in endotoxemia |
| ANGPT1 | Angiopoietin-1; stabilizes endothelial junctions | Negative regulator of permeability |
| S1PR1 | Sphingosine-1-phosphate receptor; enhances barrier integrity | Counteracts permeability |
| HIF1A | Hypoxia-inducible factor; induces VEGF expression | Links hypoxia to permeability in tumors |
| NFKB1 | Transcription factor driving inflammatory gene expression including VEGF | Mediates cytokine-induced permeability |
| TLR4 | Toll-like receptor sensing LPS; triggers permeability in sepsis | Involved in S100A8/A9 release |
| ACE2 | Receptor for SARS-CoV-2; associated with endothelial dysfunction | Linked to COVID-19 vascular permeability |
| IL6 | Cytokine that increases vascular permeability in inflammation | Therapeutic target in cytokine storm |
How Is positive regulation of vascular permeability Regulated?
The positive regulation of vascular permeability is tightly controlled by a balance of pro- and anti-permeability signals. VEGF-A is the master positive regulator, but its effects are modulated by co-receptors like Neuropilin-1 and downstream effectors such as PLCβ2. Negative feedback is provided by Robo4, which is upregulated by SMAD signaling and suppresses permeability in endotoxemia and COVID-19 models. Additionally, S100A8/A9 amplifies permeability in sepsis, and its deficiency is protective. Therapeutic strategies aim to either block positive regulators (e.g., anti-VEGF agents) or enhance negative regulators (e.g., Robo4 agonists) to restore barrier function.
positive regulation of vascular permeability and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| VEGFA | Cancer, retinal edema, diabetic retinopathy | Xenograft tumors, oxygen-induced retinopathy (OIR) mouse model |
| S100A8/A9 | Sepsis, acute lung injury | LPS-induced septic mice, S100A8/A9 KO mice |
| ROBO4 | Endotoxemia, COVID-19 | LPS-induced endotoxemia, SARS-CoV-2 infection models |
| NRP1 | Angiogenesis, inflammation | Endothelial-specific Nrp1 KO mice, permeability assays |
| PLCB2 | VEGF-induced permeability | Plcb2 KO mice, Miles assay |
Vascular Permeability in Cancer and Tumor Microenvironment
In cancer, tumor cells secrete VEGF-A, which increases vascular permeability and promotes metastasis, immune evasion, and poor drug delivery. Anti-VEGF therapies can normalize tumor vessels, reducing permeability and improving immune cell infiltration, as shown in preclinical models. Sustained suppression of VEGF is also used to treat retinal and choroidal vascular diseases characterized by excessive permeability. Thus, targeting positive regulation of vascular permeability is a validated strategy in oncology and ophthalmology.
Sepsis and Acute Inflammatory Conditions
Sepsis is characterized by systemic inflammation and vascular leak, leading to organ failure. S100A8/A9 deficiency attenuates pulmonary microvascular leakage in septic mice, highlighting its role as a positive regulator. Robo4 upregulation suppresses vascular permeability and mortality in endotoxemia models, suggesting a protective strategy. These findings underscore the importance of permeability control in critical care.
COVID-19 and Endothelial Dysfunction
COVID-19 is associated with endothelial dysfunction and increased vascular permeability, contributing to severe respiratory distress. Upregulation of Robo4 by SMAD signaling suppresses vascular permeability and mortality in COVID-19 models, indicating a potential therapeutic avenue. The interplay between SARS-CoV-2 and endothelial barrier function is an active area of research.
Lymphedema and Lymphatic Disorders
Lymphedema involves impaired lymphatic drainage and altered vascular permeability, leading to tissue swelling. Recent reviews highlight mechanisms and treatments, including molecular targets that modulate permeability. Understanding positive regulation of vascular permeability in lymphatic vessels may offer new therapeutic options.
From positive regulation of vascular permeability-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X causally increase vascular permeability? | Endothelial-specific knockout (KO) in mice followed by Miles assay or Evans blue extravasation |
| Does a specific point mutation in gene Y alter permeability? | Point-mutation knock-in mice (e.g., phospho-dead VE-cadherin) |
| Can overexpression of gene Z suppress permeability? | Endothelial-specific overexpression via transgenic or viral vectors |
| What is the role of gene W in sepsis-induced leak? | LPS-induced endotoxemia in KO mice, measuring pulmonary microvascular leakage |
| How does gene V affect tumor vessel normalization? | Tumor xenografts in KO or overexpression models, assessing perfusion and immune infiltration |
| Can CRISPR screen identify novel permeability regulators? | Genome-wide CRISPR KO screen in endothelial cells followed by permeability assay |
How to Study the positive regulation of vascular permeability Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Miles assay | Albumin extravasation in vivo | Quantifying vascular permeability in mice after VEGF or histamine |
| Evans blue dye extravasation | Vascular leak in tissues | Assessing pulmonary or dermal permeability in sepsis models |
| Transwell permeability assay | Flux of fluorescent dextran across endothelial monolayer | In vitro barrier function after gene knockout |
| TEER measurement | Electrical resistance of endothelial monolayer | Real-time monitoring of barrier integrity |
| Immunofluorescence | Localization of VE-cadherin and junctional proteins | Visualizing adherens junction disruption |
| Phosphoproteomics | Global phosphorylation changes | Identifying signaling pathways downstream of VEGF |
| CRISPR screen | Gene essentiality for permeability phenotype | Discovery of novel regulators |
| RNA-seq | Transcriptional changes | Profiling gene expression in endothelial cells |
In Vivo Permeability Assays
The Miles assay and Evans blue dye extravasation are classic methods to measure vascular permeability in animal models. These assays quantify the leakage of albumin-bound dye from blood vessels into tissues after challenge with permeability-inducing agents like VEGF. They are widely used to validate genetic models and test therapeutics.
Endothelial Barrier Function In Vitro
Transwell assays and electric cell-substrate impedance sensing (ECIS) measure the integrity of endothelial monolayers. Treatment with VEGF or other inducers decreases transendothelial electrical resistance (TEER), reflecting increased permeability. These systems allow mechanistic studies of junctional proteins and signaling pathways.
Imaging and Junction Analysis
Immunofluorescence microscopy of VE-cadherin and other junctional proteins reveals internalization or disruption upon permeability induction. Live-cell imaging can track gap formation and cytoskeletal changes. These methods provide spatial and temporal resolution of barrier disruption.
Genomic and Proteomic Approaches
RNA-seq and proteomics can identify global changes in gene expression and protein phosphorylation during permeability regulation. Phosphoproteomics of endothelial cells treated with VEGF reveals signaling nodes like PLCβ2. CRISPR screens coupled with permeability readouts enable unbiased discovery of novel regulators.
How CRISPR Can Be Used to Study GO:0043117 positive regulation of vascular permeability
Knockout
CRISPR knockout of candidate genes in endothelial cells or mice is used to determine whether a gene is required for positive regulation of vascular permeability. For example, knockout of Nrp1 or Plcb2 reduces VEGF-induced permeability. Endothelial-specific knockout avoids developmental lethality and allows adult studies.
Point Mutation
Point mutations can be introduced to dissect specific phosphorylation sites or domains. For instance, mutating VE-cadherin phosphorylation sites can prevent its internalization and block permeability. This approach provides mechanistic insights beyond simple knockout.
Knock-in
Knock-in of reporter genes or tagged proteins allows visualization and quantification of permeability regulators in real time. Tagged VE-cadherin knock-in mice enable live imaging of junctional dynamics. Knock-in of human disease variants can model patient-specific permeability defects.
Overexpression
Overexpression of negative regulators such as Robo4 or SMAD components can suppress vascular permeability and protect against endotoxemia. Conversely, overexpression of VEGF or S100A8/A9 increases permeability. These models are valuable for testing therapeutic hypotheses.
How EDITGENE Supports positive regulation of vascular permeability Research
Researchers studying positive regulation of vascular permeability-related genes often need to determine whether a candidate gene is causally involved in barrier disruption or protection. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell and animal models, enabling rigorous functional validation of permeability regulators.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of vascular permeability research.
Frequently Asked Questions About positive regulation of vascular permeability
What is GO:0043117 positive regulation of vascular permeability?
GO:0043117 is a Gene Ontology biological process term defined as any process that increases the extent to which blood vessels can be pervaded by fluid. It encompasses molecular events that make blood vessel walls leakier, often in response to factors like VEGF.
What genes are involved in positive regulation of vascular permeability?
Key genes include VEGFA, NRP1, PLCB2, S100A8/A9, ROBO4, KDR (VEGFR2), CDH5 (VE-cadherin), and RHOA, among others.
How does VEGF increase vascular permeability?
VEGF-A binds VEGFR2 on endothelial cells, triggering signaling cascades that disrupt adherens junctions, induce cytoskeletal contraction, and create gaps between cells, allowing fluid to leak out.
What diseases are associated with increased vascular permeability?
Increased vascular permeability is linked to sepsis, COVID-19, cancer, retinal edema, diabetic retinopathy, and lymphedema.
How can I study positive regulation of vascular permeability in the lab?
Common methods include Miles assay, Evans blue extravasation, Transwell permeability assays, TEER measurements, and immunofluorescence for junctional proteins.
What is the role of Neuropilin-1 in vascular permeability?
Neuropilin-1 controls vascular permeability through juxtacrine regulation of endothelial adherens junctions, modulating VEGF signaling.
Can CRISPR be used to study vascular permeability genes?
Yes, CRISPR knockout, knock-in, point mutation, and overexpression models are powerful tools to dissect gene function in vascular permeability.
What is the difference between positive and negative regulation of vascular permeability?
Positive regulation increases leakiness (GO:0043117), while negative regulation decreases it. Both are essential for maintaining vascular homeostasis.
What is the role of S100A8/A9 in vascular permeability?
S100A8/A9 promotes microvascular leakage in sepsis; its deficiency attenuates pulmonary vascular leak in mice.
How does Robo4 suppress vascular permeability?
Robo4 upregulation by SMAD signaling enhances endothelial barrier integrity and suppresses permeability in endotoxemia and COVID-19 models.
Conclusion
GO:0043117 positive regulation of vascular permeability is a fundamental biological process with profound implications for human health and disease. From VEGF-driven edema in cancer and sepsis to protective mechanisms involving Robo4, the molecular players are increasingly well-defined. Continued research using CRISPR-based models and advanced imaging will uncover new therapeutic targets. EDITGENE stands ready to support these efforts with comprehensive gene editing and screening services.
References
- 1. Pal S et al.. 2024. Neuropilin-1 controls vascular permeability through juxtacrine regulation of endothelial adherens junctions.. Angiogenesis 28(1):7 PMID: 39668325
- 2. Tian L et al.. 2017. Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming.. Nature 544(7649):250-254 PMID: 28371798
- 3. Phoenix KN et al.. 2022. PLCβ2 Promotes VEGF-Induced Vascular Permeability.. Arterioscler Thromb Vasc Biol 42(10):1229-1241 PMID: 35861069
- 4. Ren H et al.. 2026. Mechanisms and treatments of lymphedema.. Front Immunol 17:1827439 PMID: 42112379
- 5. Yu J et al.. 2023. Deficiency of S100A8/A9 attenuates pulmonary microvascular leakage in septic mice.. Respir Res 24(1):288 PMID: 37978525
- 6. Morita M et al.. 2023. Upregulation of Robo4 expression by SMAD signaling suppresses vascular permeability and mortality in endotoxemia and COVID-19 models.. Proc Natl Acad Sci U S A 120(3):e2213317120 PMID: 36634143
- 7. Ribatti D. 2005. The crucial role of vascular permeability factor/vascular endothelial growth factor in angiogenesis: a historical review.. Br J Haematol 128(3):303-9 PMID: 15667531
- 8. Campochiaro PA et al.. 2021. Sustained suppression of VEGF for treatment of retinal/choroidal vascular diseases.. Prog Retin Eye Res 83:100921 PMID: 33248215
